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Cardiologist in the Carotids
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eattle, Washington
Carotid endarterectomy for stroke prevention has been the standard of care for 50 years in
patients with extra-cranial carotid bifurcation disease. Over the past decade, carotid stenting
has emerged as a viable alternative to surgery. Combined with filter embolic protection
devices, both a randomized control trial (Stenting and Angioplasty with Protection in
Patients at High Risk for Endarterectomy registry [SAPPHIRE]) as well as registry data
(ACCULINK for Revascularization of Carotids in High Risk Patients registry [ARCHeR]
and Registry Study to evaluate the Neuroshield Bare-Wire Cerebral Protection System and
X-Act Stent in patients at high risk for Carotid Endarterectomy [SECuRITY]) have
compared favorably to endarterectomy in patients at high risk for operative revascularization.
Conditions associated with high operative risk included patients with significant cardiac,
pulmonary, and renal disease; previous neck operation; previous radiation; and anatomically
difficult surgical access. On the basis of these results, a carotid stent system approved by the
Food and Drug Administration (FDA) is anticipated in 2004. Although this will be a
welcome addition to endarterectomy in the armamentarium of therapeutic options for patients
with carotid disease, several challenges lie ahead. Coverage and reimbursement for the carotid
stenting has been severely restricted to include only those procedures performed as part of an FDA
investigational device exemption trial protocol, and a national noncoverage decision will have to
be reckoned with before broader coverage can be put into place (assuming FDA approval). In
addition, the level of national expertise in carotid endovascular intervention is limited, and training
will need to be tailored to the three specialties likely to perform the procedure: cardiology,
radiology, and vascular surgery. Each of these specialties will have specific, and different,
requirements for their training, further complicating the task of education. (J Am Coll Cardiol
2004;43:1602–5) © 2004 by the American College of Cardiology Foundationi
e
s
a
h
s
d
r
o
o
n
t
e
t
t
c
l
i
m
l
f
t
n
carotid surgery is celebrating an important milestone this
ear. Depending on the published report, it is the 50th (or
1st) anniversary of the first endarterectomy for obstructive
isease (1,2). In skilled hands and appropriate patients, this
s an elegant and effective operation. Endarterectomy nev-
rtheless required almost 40 years, largely without opposi-
ion and in a fully reimbursed environment, to demonstrate
uperiority to medical therapy for low-surgical-risk symp-
omatic patients (3–5). It is now being gradually supplanted
y a nonsurgical technique that is only a few years old and
ot currently practiced by most surgeons. In significantly
ess time and in a more difficult regulatory and reimburse-
ent environment, carotid stenting appears to have
chieved parity in the high-surgical-risk population and
ncreasing popularity among patients. How did this come to
e, what data are available to support this apparent para-
igm shift, and what are the future implications for carotid
rtery disease management?
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n the early 1980s, with the work of Mathias (6) and Theron
t al. (7) on carotid angioplasty. In the U.S., its practice was
poradic until the mid-1990s, when Deitrich (a surgeon)
nd then Roubin (a cardiologist) expanded its use, largely in
igh-risk patients. A progression in technique and move to
elf-expanding stents, albeit tracheobronchial (the only
evices with enough delivery length to reach the carotid),
esulted in improved outcomes, and early published reports
f stroke and death ranged from 7% to 11% (8,9). In
bserving these early efforts, the majority of vascular surgery
ational leaders, along with their societies, did not serve
heir constituency well. Rather than approaching the
merging carotid stent method as a potential adjunct to
heir care of the patient with carotid disease—therefore in
heir domain—and integrating into the investigational pro-
ess going forward, a pitched, all-or-nothing strategy to
imit its use and demonize its practitioners was chosen
nstead (10,11). This has been unfortunate not only for
any surgeons who now find themselves on the outside
ooking in (the majority of procedures currently are per-
ormed by cardiologists) (12,13) but also, and more impor-
antly, for patients whose option to choose a more conve-
ient, less invasive, and potentially safer treatment
ontinues to be delayed.
On the basis of the promise of these and other early
eports from single centers, further research and device
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ol stents and embolic protection devices, which have led to
mproved outcomes (14–19). But what are the most recent
elevant clinical data? In the first randomized multicenter
tudy ever performed to examine the role of endarterectomy
n the management of the high-surgical-risk patient, the
andmark Stenting and Angioplasty with Protection in
atients at High Risk for Endarterectomy (SAPPHIRE)
rial enrolled 307 patients with high-risk characteristics to
ither endarterectomy or carotid stenting with filter embolic
rotection. Patients were eligible if they had severe carotid
tenosis and the following characteristics, putting them at
igher-than-usual risk for surgical revascularization: two or
ore severely stenosed coronary arteries, unstable angina,
yocardial infarction in the previous 30 days, concurrent
eed for bypass or valve surgery, contralateral carotid artery
cclusion, need for major organ transplantation, significant
eft ventricular dysfunction or significant clinical congestive
eart failure, forced expiratory volume (FEV) 30%,
ialysis-dependent renal failure, uncontrolled diabetes mel-
itus, previous radical neck surgery, previous neck irradia-
ion, spinal immobility, contralateral laryngeal nerve paral-
sis, or severe restenosis after prior endarterectomy. These
atients are commonly encountered in clinical practice and
ere excluded from previous randomized trials examining
ndarterectomy versus medical therapy but, based on ex-
rapolations from the previous “low-risk” data, nevertheless
ontinue undergo operations. Another 408 patients in
APPHIRE were treated with stenting in a registry de-
igned to accommodate those whom the surgeons judged an
perative risk to be excessive or prohibitive. The 30-day
utcomes for the composite end point of stroke, myocardial
nfarction, and death for the randomized groups were
triking: 5.8% for the stent arm and 12.6% for the surgical
rm (p  0.047) (20); these differences have continued at
he one-year analysis. In the surgical refusal registry, the
0-day composite end point was 7.8%. These data have
een confirmed in two separate prospective multicenter
rials: ACCULINK for Revascularization of Carotids in
igh Risk Patients (ARCHeR) registry in high-surgical-
isk patients enrolled in a nonrandomized registry, with the
Abbreviations and Acronyms
ARCHeR  ACCULINK for Revascularization of
Carotids in High Risk Patients registry
FDA  Food and Drug Administration
IDE  Investigational Device Exemption
SAPPHIRE  Stenting and Angioplasty with Protection
in Patients at High Risk for
Endarterectomy registry
SECuRITY  Registry Study to evaluate the
Neuroshield Bare-Wire Cerebral
Protection System and X-Act Stent in
patients at high risk for Carotid
Endarterectomyame 7.8% rate of stroke, myocardial infarction, and death i21) and the Registry Study to evaluate the Neuroshield
are-Wire Cerebral Protection System and X-Act Stent in
atients at high risk for Carotid Endarterectomy
SECuRITY) demonstrated a rate of 7.2% for the same
0-day end points. The SAPPHIRE, ARCHeR, and SE-
uRITY results demonstrate a robust consistency in out-
omes across trials, devices, and operators. Other registries
re to report 30-day outcomes this year and appear to be on
imilar tracks. One-year data in SAPPHIRE and ARCHeR
emonstrate ipsilateral major/fatal stroke rates of approxi-
ately 1.5%, comparable to many low-risk endarterectomy
rials. After analyzing the results, it has been suggested by
ome enlightened surgical colleagues that once stent systems
re approved, it will be unethical to offer these patients
urgery instead of stenting, much less fail to even discuss it,
ssuming stenting with embolic protection is available in
heir community from trained and expert operators, includ-
ng potentially themselves.
Recent data on cost and length of stay are also compel-
ing. In a single-center comparison of resource use, stenting
esulted in patients’ length of stay at the hospital being 50%
horter than patients undergoing endarterectomy and with
imilar clinical outcomes (22). Although this study found
hat hospital costs for stent patients were one-third less than
urgery, it did not include the cost, nor benefits, of embolic
rotection devices, which will likely mitigate differences in
irect hospital costs. In a separate analysis of 100 random-
zed patients at a single-center either operated on or stented
y the same surgeon, the length of stay for stenting was
gain 50% that of surgery, and in an interesting analysis
ound that patients returned to full activity more frequently
ithin a week after stenting compared with surgery (23).
Although these objective results are remarkable, the pace
f patient access to the procedure has been slowed by the
ontinued open opposition of nonaligned physicians at local
evels making patient recruitment difficult, along with an
dverse regulatory and reimbursement environment, in no
mall part the result of intense lobbying at a national level.
espite these considerable obstacles to adoption and test-
ng, carotid stenting has achieved at least parity in the
igh-surgical-risk patient, and quite possibly superiority, to
urgery in these multi- and single-center head-to-head
omparisons and single-arm registries. The lack of broad
ospital reimbursement, limited currently by the Centers for
edicare and Medicaid Services (formerly Health Care
inancing Administration) to Food and Drug Administra-
ion (FDA) to Investigational Device Exemption trial re-
uirements, makes the barriers to entering this promising
eld almost prohibitive for many talented potential opera-
ors, among them surgeons attempting to embrace advanc-
ng therapies. Physicians cannot get into a trial without
revious experience of 20 to 30 procedures and cannot
erform these procedures without considerable nonreim-
ursed hospital costs or committing Medicare fraud by
illing and coding the procedure alternatively. This leads to
mportant questions as to when device approval and proce-
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A Cardiologist in the Carotids May 5, 2004:1602–5ural reimbursement will finally support the practice, to
hat extent, by whom, and how pathways to training and
redentialing will evolve.
Given the results of SAPPHIRE, ARCHeR, and SE-
uRITY, FDA approval for at least one, and possibly two,
ystems is anticipated in 2004. It is hoped that reimburse-
ent will follow closely. Unfortunately, the completion of
ost of the high-risk registries has resulted in many
xperienced investigational carotid stent programs slowing
onsiderably. This means high-risk patients’ access to a
herapy that appears at least equivalent to surgery, and
otentially safer, at accomplished centers is significantly
estricted. At a minimum, ongoing access for operators
nvolved in these trials would allow continued treatment of
hese at-risk patients. Continued NIH/NHLBI support of
he Carotid Revascularization by Endarterectomy or Stent-
ng trial currently randomizing standard-surgical-risk pa-
ients with recent nondisabling stroke or transient ischemic
ttack does maintain some access for patients, albeit in a
ifferent population, and will be important in assessing the
echnique in this key subgroup.
Endarterectomy volume in the U.S. alone is estimated to
e over 150,000 per annum. Even if the diffusion of carotid
tent and embolic protection device technology is relatively
easured and a third of these surgeries convert to endovas-
ular procedures in the first two or three years, there will be
ignificant demands placed on existing operators. Unfortu-
ately, physician training has slowed significantly because of
he national noncoverage decision proscribing reimburse-
ent for hospital costs except in a Category B FDA
nvestigational device exemption trial. This is a critical issue
ecause it has been well demonstrated that outcomes are
elated to procedural volumes (24). If after device approval
he procedure is performed by unskilled or untrained oper-
tors either trying to maintain an established carotid surgical
ractice volume or start anew, the results could be disastrous
ot only for the patient but also for the field at large. It
ould also be a gross betrayal of patient confidence.
What, then, can be done to assure adequate training for
his restricted procedure? Continued access and institutional
eimbursement are obvious prerequisites and in their ab-
ence efforts to articulate a coherent, multidiscipline-based
trategy for training and credentialing have been signifi-
antly hampered. Until the national cardiology and vascular
urgical societies weigh in on this issue, local institutional
equirements will be the key to assuring appropriately
rained operators performing these procedures and assuring
he best possible patient outcomes. Training needs will not
e uniform, and one size will not fit all given the diverse
alents of the specialties to be involved. Undoubtedly phy-
icians with credentials in other endovascular territories of
reatment will claim expertise in carotids as well, but the
evel of operator experience at entry is a crucial stratifier as
o the type and intensity of training required. A physician
ithout catheter-based skills should not start acquiringhose skills in the carotid territory and will require signifi-ant “schooling” before attempting to do so. Physicians with
udimentary peripheral 0.035-inch wire-based equipment
xperience will need training on 0.014-inch wires and
atheters and rapid-exchange systems, in addition to specific
raining in cerebrovascular access and intervention. Most
oncardiologists will require preparation in the manage-
ent of carotid body-induced asystole and hypotension or
ostprocedure hypertension to avoid cerebral hemorrhage.
hysicians with extensive 0.014-inch wire experience, the
ajority of whom will be cardiologists, will need training in
pecific device systems, anatomy, and the clinical diagnosis,
oppler, and office-based management of the neurovascular
atient. Any combination of training needs is imagin-
ble—a dearth of 0.014-inch wire experience, embolic filter
evice experience, cognitive skills related to noninvasive
esting, cerebrovascular diagnosis, management, and anato-
y—thus complicating the algorithms for training. In an
arly experience, careful case selection and proctoring of
everal cases will be critical components to maximally assure
atient safety. Institutional program development, including
ppropriate inventory, nursing education, and interventional
ab personnel training and support, is fundamental to
uccessful patient outcomes, and procedures should not be
ttempted until these important pieces are also in place.
I have been fortunate enough to be involved with carotid
tenting since visiting Alabama in 1995. The advancements
n technique and technology have been rapid and gratifying
nd have resulted in a safe treatment option for patients.
lmost a decade later, it has also been the longest interven-
ional research project, without timely approval or reim-
ursement, in which I have ever been, or hope to be,
nvolved. Although it is now generally acknowledged that
arotid stenting likely will have an expanding role in the care
f patients with bifurcation carotid disease, it is not the time
or a victory lap; much is yet to be studied and undertaken
efore carotid stenting can be broadly incorporated. How-
ver, patients clearly prefer a nonoperative means of carotid
isease management and are openly disappointed to learn of
ts unavailability even if they are otherwise good candidates
or a safe operation. They ultimately will be the primary
rivers, and beneficiaries, of a well-selected and well-
erformed procedure, and delaying their option to choose
tenting seems no longer justifiable. The time for arguing
bout the primacy of one therapy, or discipline, over the
ther has passed. . .there’s work to do.
eprint requests and correspondence: Dr. William A. Gray,
irector, Endovascular Care, Swedish Cardiovascular Research,
uite 1020, 1221 Arnold, Seattle, Washington 98104. E-mail:
illiam.gray@swedish.org.
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